A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

Study acronym: DeLLphi-309
StatusActive, Not Recruiting
PhasePhase 2
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later across 2 updates Feb 9, 2029 → Aug 10, 2029
See other at-risk trials from Amgen

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from May 10, 2029 to Aug 10, 2029
    • Eligibility criteria expanded, about 43 words
  2. Primary and study completion pushed from Feb 9, 2029 to May 10, 2029v24
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 240 to confirmed 252
    • Primary and study completion dates: Feb 13, 2029 to Feb 9, 2029
    • Site details revised at 78 of 78 sites
    v23
  4. Study sites: 76 to 78v22
  5. Re-verified, no change to tracked fieldsv21
Show 19 earlier versionsHide 19 earlier versions
  1. Study sites revised (76)v20
  2. Study sites: 75 to 76v19
  3. Study sites: 73 to 75
    • Primary and study completion dates: Dec 31, 2028 to Feb 13, 2029
    v18
  4. Study sites: 69 to 73
    • Primary and study completion dates: May 29, 2029 to Dec 31, 2028
    v17
  5. Study sites: 67 to 69v16
  6. Study sites: 63 to 67v15
  7. Study sites: 61 to 63v14
  8. Study sites: 48 to 61v13
  9. Study sites: 43 to 48v12
  10. Study sites: 36 to 43v11
  11. Study sites: 34 to 36v10
  12. Primary completion date: Nov 29, 2026 to May 29, 2029
    • Study sites: 27 to 34
    v9
  13. Study sites: 26 to 27v8
  14. Study sites: 22 to 26v7
  15. Study sites: 10 to 22v6
  16. Study sites: 3 to 10v5
  17. Secondary endpoints revised (10)v4
  18. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 3
    • Start date changed from estimate of Feb 28, 2025 to Feb 26, 2025
    v3
  19. Start date: Jan 29, 2025 to Feb 28, 2025
    • Study sites: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Lung Cancer
4,798 trials monitored
See 270 trials at risk
Small Cell Lung Cancer
564 trials monitored
See 34 trials at risk
The primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Trial Details
NCT Number NCT06745323
Lead Sponsor Amgen
Conditions
(from sponsor)		 Small Cell Lung Cancer (SCLC)
Related terms Small Cell Lung Carcinoma
Enrollment 252 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov